InChI: | InChI=1S/C15H21N3O2S3/c1-15(2,3)17-6-9(19)7-21-14-18-10(8-22-14)11-4-5-12(23-11)13(16)20/h4-5,8-9,17,19H,6-7H2,1-3H3,(H2,16,20) |
Specification: |
The IUPAC name of Arotinolol hydrochloride is 5-[2-[3-(tert-butylamino)-2-hydroxypropyl]sulfanyl-1,3-thiazol-4-yl]thiophene-2-carboxamide hydrochloride. With the CAS registry number 68377-91-3, it is also named as (+-)-2-(3'-tert-Butylamino-2'-hydroxypropylthio)-4-(5'-carbamoyl-2'-thienyl)thiazole HCl. The classification codes are Drug / Therapeutic Agent; Reproductive Effect. It is highly toxic. And it will produce toxic nitrogen oxide, sulfur oxides and hydrogen chloride fumes when buring. So the storage environment should be ventilate, low-temperature and dry. Keep Arotinolol hydrochloride separate from raw materials of food.
The other characteristics of this product can be summarized as: (1)ACD/LogP: 2.95; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): -0.04; (4)ACD/LogD (pH 7.4): 1.25; (5)ACD/BCF (pH 5.5): 1; (6)ACD/BCF (pH 7.4): 2.04; (7)ACD/KOC (pH 5.5): 1; (8)ACD/KOC (pH 7.4): 19.05; (9)#H bond acceptors: 5; (10)#H bond donors: 4; (11)#Freely Rotating Bonds: 9 ; (12)Index of Refraction: 1.646; (13)Molar Refractivity: 99.5 cm3; (14)Molar Volume: 274 cm3; (15)Polarizability: 39.44×10-24 cm3; (16)Surface Tension: 67.8 dyne/cm; (17)Enthalpy of Vaporization: 93.9 kJ/mol; (18)Vapour Pressure: 3.09E-15 mmHg at 25°C; (19)Rotatable Bond Count: 8; (20)Tautomer Count: 2; (21)Exact Mass: 407.056267; (22)MonoIsotopic Mass: 407.056267; (23)Topological Polar Surface Area: 170; (24)Heavy Atom Count: 24; (25)Complexity: 406.
People can use the following data to convert to the molecule structure.
1. Smiles:c1(ccc(s1)c1nc(sc1)SC[C@@H](CNC(C)(C)C)O)C(=O)N.Cl
2. InChI:InChI=1/C15H21N3O2S3.ClH/c1-15(2,3)17-6-9(19)7-21-14-18-10(8-22-14)11-4-5-12(23-11)13(16)20;/h4-5,8-9,17,19H,6-7H2,1-3H3,(H2,16,20);1H
The following are the toxicity data which has been tested.
Organism |
Test Type |
Route |
Reported Dose (Normalized Dose) |
Effect |
Source |
mouse |
LD50 |
intraperitoneal |
360mg/kg (360mg/kg) |
|
Drugs of the Future. Vol. 4, Pg. 442, 1979. |
mouse |
LD50 |
intravenous |
69mg/kg (69mg/kg) |
|
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 17, Pg. 365, 1986. |
mouse |
LD50 |
oral |
5gm/kg (5000mg/kg) |
|
Drugs of the Future. Vol. 4, Pg. 442, 1979. |
mouse |
LD50 |
subcutaneous |
> 1gm/kg (1000mg/kg) |
|
Drugs in Japan Vol. -, Pg. 471, 1995. |
rat |
LD50 |
intraperitoneal |
340mg/kg (340mg/kg) |
|
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 17, Pg. 365, 1986. |
rat |
LD50 |
intravenous |
> 25mg/kg (25mg/kg) |
|
Drugs in Japan Vol. -, Pg. 471, 1995. |
rat |
LD50 |
oral |
86mg/kg (86mg/kg) |
|
Drugs of the Future. Vol. 4, Pg. 442, 1979. |
rat |
LD50 |
subcutaneous |
> 1gm/kg (1000mg/kg) |
|
Drugs in Japan Vol. -, Pg. 471, 1995. |
|